The Cancer Institute is a leader in cutting-edge treatments. Using a truly multidisciplinary approach, patients have access to advanced diagnostics, minimally invasive surgical interventions, and personalized genomic and immune-oncologic treatment options. Our team of cancer specialists – many of whom completed fellowships and specialty training at prestigious academic centers – offers comprehensive services for individuals with a cancer diagnosis.

Follow

Submissions from 2022

Link

The Human Tumor Atlas Network's beginning steps toward the future of collaborative multi-omic discovery., David B Page

Link

Brain radiotherapy, tremelimumab-mediated CTLA-4-directed blockade +/- trastuzumab in patients with breast cancer brain metastases., David B Page, Kathryn Beal, Stefanie N Linch, Kateri Spinelli, Micaela Rodine, Darragh Halpenny, Shanu Modi, Sujata Patil, Robert J Young, Thomas Kaley, Taha Merghoub, David Redmond, Phillip Wong, Christopher A Barker, Adi Diab, Larry Norton, and Heather L McArthur

Applications of statistical regression to improve the TIL score and other immune-based biomarkers in breast cancer, DB Page

Link

Zandelisib with continuous or intermittent dosing as monotherapy or in combination with rituximab in patients with relapsed or refractory B-cell malignancy: a multicentre, first-in-patient, dose-escalation and dose-expansion, phase 1b trial., John M Pagel, Jacob D Soumerai, Nishitha Reddy, Deepa Jagadeesh, Anastasios Stathis, Adam Asch, Huda Salman, Vaishalee P Kenkre, Alexia Iasonos, Judith Llorin-Sangalang, Joanne Li, and Andrew D Zelenetz

Link

Molecular alterations associated with improved outcome in patients with glioblastoma treated with Tumor-Treating Fields., Manjari Pandey, Joanne Xiu, Sandeep Mittal, Jia Zeng, Michelle Saul, Santosh Kesari, Amir Azadi, Herbert Newton, Karina Deniz, Katherine Ladner, Ashley Sumrall, W Michael Korn, and Emil Lou

172P Phase I study of JTX-8064, a LILRB2 (ILT4) inhibitor, as monotherapy and combination with pimivalimab (pimi), a PD-1 inhibitor (PD-1i), in patients (pts) with advanced solid tumors, K Papadopoulos, Rachel Sanborn, and See all authors in comments

1296 ­Radiomics-based multi-modal prediction of treatment response to PD-1/PD-L1 immune checkpoint inhibitor (ICI) therapy in stage IV non-small cell lung carcinoma (mNSCLC), Ravi Parikh, Brendan Curti, Roshanthi Weerasinghe, and See all authors in comments

Link

Chemoradiation therapy alters the PD-L1 score in locoregional recurrent squamous cell carcinomas of the head and neck., Brian J Park, Austin K Mattox, Daniel Clayburgh, Mihir Patel, R Bryan Bell, Bevan Yueh, Rom Leidner, Hong Xiao, Marcus Couey, Shiting Li, Tingting Qin, Maureen A Sartor, Belinda Cairns, Tracy MacDonough, Kyle Halliwill, Daniel Deschler, Derrick T Lin, William C Faquin, Peter M Sadow, and Sara I Pai

Link

A single-cell based precision medicine approach using glioblastoma patient-specific models., James H Park, Abdullah H Feroze, Samuel N Emerson, Anca B Mihalas, C Dirk Keene, Patrick J Cimino, Adrian Lopez Garcia de Lomana, Kavya Kannan, Wei-Ju Wu, Serdar Turkarslan, Nitin S Baliga, and Anoop P Patel

Link

Posterior Ischemic Optic Neuropathy Because of Hematologic Malignancy., Ankush U Patel, Uresh S Patel, and Eugene F May

Link

Effect of a Community Health Worker Intervention on Acute Care Use, Advance Care Planning, and Patient-Reported Outcomes Among Adults With Advanced Stages of Cancer: A Randomized Clinical Trial., Manali I Patel, Kristopher Kapphahn, Marilyn Dewland, Veronica Aguilar, Blanca Sanchez, Etsegenet Sisay, Ariana Murillo, Kim Smith, and David J Park

Link

#754 A PHASE 1/2 STUDY OF ASP1570 IN PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS WHO HAVE PROGRESSED ON, OR ARE INELIGIBLE FOR, ALL AVAILABLE STANDARD THERAPIES, Manish Patel, David J Park, and See full list of authors in comments

Link

A PHASE 1/2 STUDY OF ASP1570 IN PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS WHO HAVE PROGRESSED ON, OR ARE INELIGIBLE FOR, ALL AVAILABLE STANDARD THERAPIES, Manish Patel, David J Park, and See full list of authors in comments

A PHASE 1/2 STUDY OF ASP1570 IN PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS WHO HAVE PROGRESSED ON, OR ARE INELIGIBLE FOR, ALL AVAILABLE STANDARD THERAPIES, Manish Patel, David Park, and See all authors in comments

Link

MTAP loss: a possible therapeutic approach for glioblastoma., C Pawan K Patro, Nupur Biswas, Sandeep C Pingle, Feng Lin, Misa Anekoji, Lawrence D Jones, Santosh Kesari, Feng Wang, and Shashaanka Ashili

Link

Genetic polymorphisms and correlation with treatment induced cardiotoxicity and prognosis in breast cancer patients., Parvin Peddi, Peter A Fasching, Duan Liu, Emmanuel Quinaux, Nicholas J Robert, Vicente Valero, John Crown, Carla Falkson, Adam Brufsky, Julie M Cunningham, Richard M Weinshilboum, Tadeusz Pienkowski, Wolfgang Eiermann, Miguel Martín, Valerie Bee, Xiaoyan Wang, Liewei Wang, Eric Yang, Dennis J Slamon, and Sara A Hurvitz

Link

Correction: Phase 1 First-in-Human Dose Escalation and Dose Expansion Study of KLS-1 (64Zinc Aspartate) in Patients With Cancer and Neurodegenerative Diseases., Jesus A Perez, Javier J Lopez, Claudia C Torres Badillo, Jaya Gill, Santosh Kesari, Peter Novak, Max Temnikov, Roman Byshovets, and Oleg Bychkov

Link

Phase 1 First-in-Human Dose Escalation and Dose Expansion Study of KLS-1 (64Zinc Aspartate) in Patients With Cancer and Neurodegenerative Diseases., Jesus A Perez, Javier J Lopez, Claudia C Torres Badillo, Jaya Gill, Santosh Kesari, Peter Novak, Max Temnikov, Roman Byshovets, and Oleg Bychkov

Real-World Evidence Insights in Cancer Research and Care, Brian D. Piening

Link

Pathogenic fusion detection in solid malignancies utilizing RNA-DNA based comprehensive genomic profiling (CGP) testing., Brian D. Piening, Alexa K Dowdell, Ryan Meng, Ann Vita, Roshanthi Weerasinghe, Alisha Stein, Bela Bapat, Brock Shroeder, Shu-Ching Chang, Lauren Harold, Mark Schmidt, Thomas R. Ward, Josiah T Wagner, Stanley Piotrowski, Phillip G. Febbo, and Carlo Bifulco

Design and Implementation of a Decentralized Virtual Molecular Tumor Board across a Large, Diverse Community Health System, Brian Piening, Patrick Foley, K Matlock, H Wright, Lauren Harold, Roshanthi Weerasinghe, A Viita, C Moung-Wen, Jacob Abel, Vassil Kaimaktchiev, A Dowdell, Ryan Meng, Walter Urba, G Srinivasa, Philip Gold, Gina Vaccaro, and Carlo Bifulco

Link

Uncovering potential interventions for pancreatic cancer patients via mathematical modeling., Daniel Plaugher, Boris Aguilar, and David Murrugarra

Link

Clinical characteristics associated with falls in patients with non-metastatic castration-resistant prostate cancer treated with apalutamide., YaoYao Pollock, Matthew R Smith, Fred Saad, Simon Chowdhury, Stéphane Oudard, Boris Hadaschik, David Olmos, Ji Youl Lee, Hiroji Uemura, Amitabha Bhaumik, Anil Londhe, Brendan Rooney, Sabine D Brookman-May, Peter De Porre, Suneel D Mundle, and Eric J Small

Link

Adjuvant and Neoadjuvant Therapies in Cutaneous Melanoma., Jay Ponto and Richard Bryan Bell

Link

The effect of race on treatment patterns and subsequent health-related quality of life outcomes in men undergoing treatment for localized prostate cancer., Natasza M Posielski, Santosh Shanmuga, On Ho, Jiji Jiang, Sally Elsamanoudi, Ryan Speir, Sean Stroup, John Musser, Alexander Ernest, Gregory T Chesnut, Timothy Tausch, John Paul Flores, and Christopher Porter

Link

Epacadostat Plus Pembrolizumab and Chemotherapy for Advanced Solid Tumors: Results from the Phase I/II ECHO-207/KEYNOTE-723 Study., John D Powderly, Samuel J Klempner, Aung Naing, Johanna Bendell, Ignacio Garrido-Laguna, Daniel V T Catenacci, Matthew H Taylor, James J Lee, Fred Zheng, Feng Zhou, Xiaohua Gong, Hema Gowda, and Gregory L Beatty

Link

CT209 / 9 - A first-in-human phase 1 trial of IO-108, an antagonist antibody targeting LILRB2 (ILT4), as monotherapy and in combination with pembrolizumab in adult patients with advanced relapsed or refractory solid tumors (NCT05054348), John Powderly, Matthew H Taylor, and See full list of authors in comments

Link

Randomized Phase III Trial of Paclitaxel and Carboplatin Versus Paclitaxel and Ifosfamide in Patients With Carcinosarcoma of the Uterus or Ovary: An NRG Oncology Trial., Matthew A Powell, Virginia L Filiaci, Martee L Hensley, Helen Q Huang, Kathleen N Moore, Krishnansu S Tewari, Larry J Copeland, Angeles A Secord, David G Mutch, Alessandro Santin, David P Warshal, Nick M Spirtos, Paul A DiSilvestro, Olga B Ioffe, and David S Miller

Link

AACR Project GENIE: 100,000 cases and beyond., Trevor J Pugh, Jonathan L Bell, Jeff P Bruce, Gary J Doherty, Matthew Galvin, Michelle F Green, Haley Hunter-Zinck, Priti Kumari, Michele L LeNoue-Newton, Marilyn M Li, James Lindsay, Tali Mazor, Andrea Ovalle, Stephen-John Sammut, Nikolaus Schultz, Thomas V Yu, Shawn M Sweeney, Brady Bernard, and Aacr Project Genie Consortium

Link

Does Residual Invasive Disease in Wide Local Excision after Diagnosis with Partial Biopsy Technique Influence Survival in Melanoma? Matched-Pair Analysis of Multicenter Selective Lymphadenectomy Trial I and II., Judi Anne B Ramiscal, Stacey L Stern, Ana K Wilson, Patrick D Lorimer, Nathaniel A Lee, Melanie R Goldfarb, Leland J Foshag, and Trevan D Fischer

Link

PTPRD and CNTNAP2 as markers of tumor aggressiveness in oligodendrogliomas., Kirsi J Rautajoki, Serafiina Jaatinen, Aliisa M Tiihonen, Matti Annala, Elisa M Vuorinen, Anni Kivinen, Minna J Rauhala, Kendra K Maass, Kristian W Pajtler, Olli Yli-Harja, Pauli Helén, Joonas Haapasalo, Hannu Haapasalo, Wei Zhang, and Matti Nykter

Link

Efficacy of oral and topical antioxidants in the prevention and management of oral mucositis in head and neck cancer patients: a systematic review and meta-analyses., Afsheen Raza, Nelli Karimyan, Amber L Watters, Chitra P Emperumal, Kamal Al-Eryani, and Reyes Enciso

Link

Follow the Data: It Is Time to Incentivize the Use of Drug-Eluting Stents and Balloons., Mahmood K Razavi

Response to aPD-1 + aLAG-3 checkpoint blockade is associated with Treg functional reprogramming and instability, William Redmond

Multimodal single-cell analysis of human TILs across multiple tumor types reveals heterogeneity and potential opportunities for personalized immunotherapy, William L. Redmond

Novel mechanisms to augment the efficacy of cancer immunotherapy, William L. Redmond

Multimodal single-cell analysis of human tumor infiltrating immune cells across multiple tumor types reveals heterogeneity and potential opportunities for personalized immunotherapeutic strategies., William L. Redmond and See full list of authors in comments

PDF

Splenic vein aneurysm: Case report of an exceedingly rare condition, Dave Riesberg

Link

Combining bempegaldesleukin (CD122-preferential IL-2 pathway agonist) and NKTR-262 (TLR7/8 agonist) improves systemic antitumor CD8, Annah S Rolig, Daniel Rose, Grace Helen McGee, Werner Rubas, Saul Kivimäe, and William L. Redmond

Response to anti-PD-1 and anti-LAG-3 immune checkpoint blockade is associated with induction of pro-inflammatory Tregs., AS Rolig, William L. Redmond, and See full list of authors in comments

Link

Gene-gene interaction of AhRwith and within the Wntcascade affects susceptibility to lung cancer., Albert Rosenberger, Nils Muttray, Rayjean J Hung, David C Christiani, Neil E Caporaso, Geoffrey Liu, Stig E Bojesen, Loic Le Marchand, Demetrios Albanes, Melinda C Aldrich, Adonina Tardon, Guillermo Fernández-Tardón, Gad Rennert, John K Field, Michael P A Davies, Triantafillos Liloglou, Lambertus A Kiemeney, Philip Lazarus, Bernadette Wendel, Aage Haugen, Shanbeh Zienolddiny, Stephen Lam, Matthew B Schabath, Angeline S Andrew, Eric J Duell, Susanne M Arnold, Gary E Goodman, Chu Chen, Jennifer A Doherty, Fiona Taylor, Angela Cox, Penella J Woll, Angela Risch, Thomas R Muley, Mikael Johansson, Paul Brennan, Maria Teresa Landi, Sanjay S Shete, Christopher I Amos, and Heike Bickeböller

Link

A Phase III, Multicenter, Randomized Controlled Trial Investigating 1-cm Versus 2-cm Surgical Excision Margins for Stage II Primary Cutaneous Melanoma (MelMarT-II)., Alexander J Rossi, Emily A Verbus, Mark Faries, Marc Moncrieff, Michael Henderson, Jonathan M Hernandez, and Michael C Lowe

Link

Uterine Sarcomas: How to Navigate an Ever-Growing List of Subtypes., Molly Roy, Fernanda Musa, Sarah E Taylor, and Marilyn Huang

Link

"Oncologic Safety of Staged Pre-Pectoral Implant Reconstruction Following Nipple-Sparing Mastectomy: a Mean 9-Year Follow-Up.", Arthur H Salibian and Jay K Harness

Novel Combinatorial Approaches with LAG-3, Rachel Sanborn

Targeting OX-40 and LAG-3 to Overcome T-cell Exhaustion, Rachel Sanborn

Vaccines and emerging immunotherapy approaches for NSCLC, Rachel Sanborn

Link

Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors., Rachel E Sanborn, Michael J Pishvaian, Margaret K Callahan, Amy Weise, Branimir I Sikic, Osama Rahma, Daniel C Cho, Naiyer A Rizvi, Mario Sznol, Jose Lutzky, Julie E Bauman, Rhonda L Bitting, Alexander Starodub, Antonio Jimeno, David A Reardon, Thomas Kaley, Fabio Iwamoto, Joachim M Baehring, Deepa S Subramaniam, Jeanny B Aragon-Ching, Thomas R Hawthorne, Tracey Rawls, Michael Yellin, and Tibor Keler

Link

Beyond Checkpoint Inhibitors: Enhancing Antitumor Immune Response in Lung Cancer., Rachel E Sanborn, Famke L Schneiders, Suresh Senan, and Shirish M Gadgeel

Results from a phase 1 study of CDX-1140, a fully human anti-CD40 agonist monoclonal antibody (mAb), in combination with pembrolizumab, Rachel E. Sanborn and See all authors in comments

Link

Beyond Checkpoint Inhibitors: Enhancing Antitumor Immune Response in Lung Cancer, Rachel E Sanborn and See full list of authors in comments

Candidate antigens for a ductal carcinoma in situ vaccine, essential for breast cancer cell survival across multiple subtypes, are immunogenic in DCIS and IBC, SE Sanborn

Link

Disparities in the impact of the AJCC 8th edition staging system on differentiated thyroid cancer outcomes., Juan A Santamaria-Barria, Amanda N Graff-Baker, Shu-Ching Chang, Adam Khader, Anthony J Scholer, Mary Garland-Kledzik, and Melanie Goldfarb

Link

Analytic pipelines to assess the relationship between immune response and germline genetics in human tumors., Rosalyn W Sayaman, Mohamad Saad, Carolina Heimann, Donglei Hu, Khalid Kunji, Jessica Roelands, Denise M Wolf, Scott Huntsman, Michele Ceccarelli, Vésteinn Thorsson, Elad Ziv, and Davide Bedognetti

Link

Accounting for EGFR Mutations in Epidemiologic Analyses of Non-Small Cell Lung Cancers: Examples Based on the International Lung Cancer Consortium Data., Sabine Schmid, Mei Jiang, M Catherine Brown, Aline Fares, Miguel Garcia, Joelle Soriano, Mei Dong, Sera Thomas, Takashi Kohno, Leticia Ferro Leal, Nancy Diao, Juntao Xie, Zhichao Wang, David Zaridze, Ivana Holcatova, Jolanta Lissowska, Beata Świątkowska, Dana Mates, Milan Savic, Angela S Wenzlaff, Curtis C Harris, Neil E Caporaso, Hongxia Ma, Guillermo Fernandez-Tardon, Matthew J Barnett, Gary E Goodman, Michael P A Davies, Mónica Pérez-Ríos, Fiona Taylor, Eric J Duell, Ben Schoettker, Hermann Brenner, Angeline Andrew, Angela Cox, Alberto Ruano-Ravina, John K Field, Loic Le Marchand, Ying Wang, Chu Chen, Adonina Tardon, Sanjay Shete, Matthew B Schabath, Hongbing Shen, Maria Teresa Landi, Brid M Ryan, Ann G Schwartz, Lihong Qi, Lori C Sakoda, Paul Brennan, Ping Yang, Jie Zhang, David C Christiani, Rui Manuel Reis, Kouya Shiraishi, Rayjean J Hung, Wei Xu, and Geoffrey Liu

Link

Validating biologic age in selecting elderly patients with pancreatic cancer for surgical resection., Anthony J Scholer, Rebecca Marcus, Mary Garland-Kledzik, Shu-Ching Chang, Adam Khader, Juan Santamaria-Barria, Zeljka Jutric, Ronald Wolf, and Melanie Goldfarb

Link

Detection of perillyl alcohol and its metabolite perillic acid in postsurgical glioblastoma tissue after intranasal administration of NEO100: illustrative case., Axel H Schönthal, Steve Swenson, Phillip A Bonney, Naveed Wagle, Vincent F Simmon, Anna J Mathew, Kyle M Hurth, and Thomas C Chen

Link

A Phase II Study Investigating Cabozantinib in Patients with Refractory Metastatic Colorectal Cancer (AGICC 17CRC01)., Aaron J Scott, Atrayee Basu Mallick, Efrat Dotan, Steven J Cohen, Philip J Gold, Howard S Hochster, Somasundaram Subramaniam, Afsaneh Barzi, George S Watts, Patrick J Blatchford, and Wells A Messersmith

Link

The diverse landscape of dermatologic toxicities of non-immune checkpoint inhibitor monoclonal antibody-based cancer therapy., Riyad N H Seervai, Sarah K Friske, Emily Y Chu, Rhea Phillips, Kelly C Nelson, Auris Huen, Woo Cheal Cho, Phyu P Aung, Carlos A Torres-Cabala, Victor G Prieto, and Jonathan L Curry

Link

Mechanisms of dermatologic toxicities to immune checkpoint inhibitor cancer therapies., Riyad N H Seervai, Avilasha Sinha, and Rajan P Kulkarni

Link

Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study., Alison Sehgal, Daanish Hoda, Peter A Riedell, Nilanjan Ghosh, Mehdi Hamadani, Gerhard C Hildebrandt, John E Godwin, Patrick M Reagan, Nina Wagner-Johnston, James Essell, Rajneesh Nath, Scott R Solomon, Rebecca Champion, Edward Licitra, Suzanne Fanning, Neel Gupta, Ronald Dubowy, Aleco D'Andrea, Lei Wang, Ken Ogasawara, Jerill Thorpe, and Leo I Gordon

Link

Glioblastoma Embryonic-like Stem Cells Exhibit Immune-Evasive Phenotype., Borja Sesé, Sandra Íñiguez-Muñoz, Miquel Ensenyat-Mendez, Pere Llinàs-Arias, Guillem Ramis, Javier I Orozco, Silvia Fernández de Mattos, Priam Villalonga, and Diego M Marzese

Link

The impact of mentoring on early career faculty: Assessment of a virtual mentoring program., Akanksha Sharma, Heather Leeper, Soo Bang, Donna Molaie, and Alyx B. Porter

Link

Advances in the Diagnosis and Treatment of Leptomeningeal Disease., Akanksha Sharma, Justin T Low, and Priya Kumthekar

Link

Comparison of perioperative outcomes following transperitoneal versus retroperitoneal robot-assisted partial nephrectomy: a propensity-matched analysis of VCQI database., Gopal Sharma, Milap Shah, Puneet Ahluwalia, Prokar Dasgupta, Benjamin J Challacombe, Mahendra Bhandari, Rajesh Ahlawat, Sudhir Rawal, Nicolo M Buffi, Ananthkrishnan Sivaraman, James R Porter, Craig Rogers, Alexandre Mottrie, Ronney Abaza, Khoon Ho Rha, Daniel Moon, Thyavihally B Yuvaraja, Dipen J Parekh, Umberto Capitanio, Kris K Maes, Francesco Porpiglia, Levent Turkeri, and Gagan Gautam

772 A phase 1/2 dose escalation/expansion study evaluating the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of E-602, a bi-sialidase fusion protein, in advanced cancer (GLIMMER-01), Manish Sharma, Brendan Curti, and See all authors in comments

Link

Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia., Jeff P Sharman, Miklos Egyed, Wojciech Jurczak, Alan Skarbnik, John M Pagel, Ian W Flinn, Manali Kamdar, Talha Munir, Renata Walewska, Gillian Corbett, Laura Maria Fogliatto, Yair Herishanu, Versha Banerji, Steven Coutre, George Follows, Patricia Walker, Karin Karlsson, Paolo Ghia, Ann Janssens, Florence Cymbalista, Jennifer A Woyach, Emmanuelle Ferrant, William G Wierda, Veerendra Munugalavadla, Ting Yu, Min Hui Wang, and John C Byrd

Link

Immunotherapy in head and neck squamous cell carcinoma: a narrative review., Shay Sharon and R Bryan Bell

Link

The immune landscape of solid pediatric tumors., Shimaa Sherif, Jessica Roelands, William Mifsud, Eiman I Ahmed, Christophe M Raynaud, Darawan Rinchai, Abbirami Sathappan, Ata Maaz, Ayman Saleh, Erdener Ozer, Khalid A Fakhro, Borbala Mifsud, Vésteinn Thorsson, Davide Bedognetti, and Wouter R L Hendrickx

Link

Effect of 3-Dimensional, Virtual Reality Models for Surgical Planning of Robotic Prostatectomy on Trifecta Outcomes: A Randomized Clinical Trial., Joseph D Shirk, Robert Reiter, Eric M Wallen, Ray Pak, Thomas Ahlering, Ketan K Badani, and James R Porter

Link

Efficacy and safety of trifluridine/tipiracil in older and younger patients with metastatic gastric or gastroesophageal junction cancer: subgroup analysis of a randomized phase 3 study (TAGS)., Kohei Shitara, Toshihiko Doi, Hisashi Hosaka, Peter Thuss-Patience, Armando Santoro, Federico Longo, Ozgur Ozyilkan, Irfan Cicin, David J Park, Aziz Zaanan, Carles Pericay, Mustafa Özgüroğlu, Maria Alsina, Lukas Makris, Karim A Benhadji, and David H Ilson

Link

Abstract A27: Impact of a validated composite comorbidity score on outcomes in patients treated with CAR T-cell therapy for diffuse large B cell lymphoma (DLBCL): A multicenter real-world evidence (RWE) study, Geoffrey Shouse, Neil Bailey, Krish Patel, and See all authors in comments

Link

Impact of a Validated Composite Comorbidity Score on Outcomes in Patients Treated with CAR T-Cell Therapy for Diffuse Large B Cell Lymphoma (DLBCL): A Multicenter Real-World Evidence (RWE) Study, Geoffrey Shouse, Neil Bailey, Krish Patel, and See all authors in comments

Link

Amivantamab and lazertinib in patients with EGFR-mutant non–small cell lung (NSCLC) after progression on osimertinib and platinum-based chemotherapy: Updated results from CHRYSALIS-2., Catherine A. Shu, Rachel E Sanborn, and See full list of authors in comments

Link

A phase 1b single-arm trial of intratumoral oncolytic virus V937 in combination with pembrolizumab in patients with advanced melanoma: results from the CAPRA study., Ann W Silk, Steven O'Day, Howard L Kaufman, Jennifer Bryan, Jacqueline T Norrell, Casey Imbergamo, Daniella Portal, Edwin Zambrano-Acosta, Marisa Palmeri, Seymour Fein, Cai Wu, Leslie Guerreiro, Daniel Medina, Praveen K Bommareddy, Andrew Zloza, Bernard A Fox, Carmen Ballesteros-Merino, Yixin Ren, Darren Shafren, Mark Grose, Joshua A Vieth, and Janice M Mehnert

Link

ASO Visual Abstract: Recurrence and Survival Rates for 1400 Early Breast Tumors Treated with Intraoperative Radiation Therapy (IORT)., Melvin J Silverstein, Melinda Epstein, Peter Chen, Kevin Lin, Sadia Khan, Lincoln Snyder, Colleen Coleman, Lisa Guerra, Farideh Dehkordi-Vakil, and Brian Kim

PDF

Psychometric Characteristics and Validity of the PROMIS Cancer Function Brief 3D Profile, Sean R. Smith, Mary Vargo, David S Zucker, Samman Shahpar, Lynn Gerber, Maryanne Henderson, Gina Jay, Minji Lee, and Andrea Cheville

PDF

Psychometric Characteristics and Validity of the PROMIS Cancer Function Brief 3D Profile, Sean R. Smith, Mary Vargo, David S Zucker, Samman Shahpar, Lynn Gerber, Maryanne Henderson, Gina Jay, Minji Lee, and Andrea Cheville

Link

Responsiveness and interpretation of the PROMIS Cancer Function Brief 3D Profile., Sean R Smith, Mary Vargo, David S Zucker, Samman Shahpar, Lynn H Gerber, Maryanne Henderson, Gina Jay, and Andrea L Cheville

Link

Contemporary, national patterns of surgery after preoperative therapy for stage II/III rectal adenocarcinoma., Celine Soriano, Henry T Bahnson, Jennifer A Kaplan, Bruce Lin, Ravi Moonka, Huong T Pham, Hagen F Kennecke, and Vlad Simianu

Link

Clinical Oncology Nurse Best Practices: Palliative Care and End-of-Life Conversations., Kellie Spine, Anne Skwira-Brown, Deanna Schlifke, and Ellen Carr

Link

Exploring approaches for predictive cancer patient digital twins: Opportunities for collaboration and innovation., Eric A Stahlberg, Mohamed Abdel-Rahman, Boris Aguilar, Alireza Asadpoure, Robert A Beckman, Lynn L Borkon, Jeffrey N Bryan, Colleen M Cebulla, Young Hwan Chang, Ansu Chatterjee, Jun Deng, Sepideh Dolatshahi, Olivier Gevaert, Emily J Greenspan, Wenrui Hao, Tina Hernandez-Boussard, Pamela R Jackson, Marieke Kuijjer, Adrian Lee, Paul Macklin, Subha Madhavan, Matthew D McCoy, Navid Mohammad Mirzaei, Talayeh Razzaghi, Heber L Rocha, Leili Shahriyari, Ilya Shmulevich, Daniel G Stover, Yi Sun, Tanveer Syeda-Mahmood, Jinhua Wang, Qi Wang, and Ioannis Zervantonakis

Link

Severe breakthrough COVID-19 with a heavily mutated variant in a multiple myeloma patient 10 weeks after vaccination., Samuel D Stampfer, Marissa-Skye Goldwater, Sean Bujarski, Bernard Regidor, Wenjuan Zhang, Aaron J Feinstein, Regina Swift, Shahrooz Eshaghian, Eric Vail, and James R Berenson

A phase I dose escalation study of STEMVAC, a multi-antigen, multi-epitope Th1 selective plasmid-based vaccine, targeting stem cell associated proteins in patients with advanced breast cancer, S Stanton

Systemic therapy strategies in triple negative breast cancer, S Stanton

Neoadjuvant survivin-targeted immunotherapy maveropepimut-S (MVP-S) to increase Th1 immune response in Ki67-high hormone receptor-positive (HR+) early-stage breast cancer (ESBC)., Sasha Stanton

Link

549 Booster vaccination of a HER2 helper T-cell vaccine increased HER2 immunity in metastatic HER2 positive breast cancer., Sasha Stanton, Jennifer Childs, Doreen Higgins, Angela Kask, Yi Yang, and Mary Disis

Phase I trial of the safety and immunogenicity of a tri-antigen vaccine targeting HER2, IGFBP-2, and IGF-IR in patients with non-metastatic breast cancer, Sasha E. Stanton and See all authors in comments

Link

Neoadjuvant survivin-targeted immunotherapy maveropepimut-S (MVP-S) to increase Th1 immune response in Ki67-high hormone receptor-positive (HR+) early-stage breast cancer (ESBC)., Sasha Stanton, Lisa Diana MacDonald, Staci Mellinger, Nikki Moxon, Tracy L. Kelly, Heather Ann Hirsch, Stephan Fiset, Kristina H Young, and David B Page

646 Neoadjuvant immunotherapy combining maveropepimut-S (MVP-S) with letrozole decreases Ki67 and increases Th1 immune response in hormone receptor positive (HR+) early-stage breast cancer (ESBC), Sasha Stanton, David Page, Kristina Young, and See all authors in comments

Link

Abstract PR007: Candidate antigens for a ductal carcinoma in situ vaccine, essential for breast cancer cell survival across multiple subtypes, are immunogenic in DCIS and IBC, Sasha Stanton, Jason Schlumbohm, and Mary L. Disis

Neoadjuvant survivin-targeted immunotherapy maveropepimut-S (MVP-S) to increase Th1 immune response in Ki67-high hormone receptor-positive (HR+) early-stage breast cancer (ESBC), Sasha Stanton and See all authors in comments

Phase I trial of the safety and immunogenicity of a tri-antigen vaccine targeting HER2, IGFBP-2, and IGF-IR in patients with non-metastatic breast cancer, Sasha Stanton and See all authors in comments

Link

3380 / 8 - Seven autoantibody panel, validated in two independent patient serum collections, can detect women with DCIS and invasive breast cancer, Sasha Stanton and See full list of authors in comments

Link

Neoadjuvant survivin-targeted immunotherapy maveropepimut-S (MVP-S) to increase Th1 immune response in Ki67-high hormone receptor-positive (HR+) early-stage breast cancer (ESBC)., Sasha Stanton, Kristina H Young, David B Page, and See all authors in comments

Immunology 101, SE Stanton

647 Phase I studies of AgenT-797, a novel allogeneic invariant natural killer T (iNKT) cell therapy, for the treatment of patients with solid tumors or multiple myeloma, Don Stevens, Rachel Sanborn, and See all authors in comments

Link

Risk factors for reduced function in women with a history of breast cancer., Nicholas Stoyles, Andrea Cheville, David S Zucker, Blair Richards, Mary Vargo, Lynn Gerber, Samman Shahpar, Maryanne Henderson, Gina Jay, and Sean R Smith

Link

Malignant Pilomatricoma of the Lower Extremity: A Difficult and Rare Diagnosis., Chaitra Subramanyam, Paige Dyrek, Xu Yao, and Martin H Kay

Link

Blockade of interleukin 10 potentiates antitumour immune function in human colorectal cancer liver metastases., Kevin M Sullivan, Xiuyun Jiang, Prajna Guha, Christopher Lausted, Jason A Carter, Cynthia Hsu, Kevin P Labadie, Karan Kohli, Heidi L Kenerson, Sara K Daniel, Xiaowei Yan, Changting Meng, Arezou Abbasi, Marina Chan, Y David Seo, James O Park, Ian Nicholas Crispe, Raymond S Yeung, Teresa S Kim, Taranjit S Gujral, Qiang Tian, Steven C Katz, and Venu G Pillarisetty